Wecome Pharmaceutical Co Ltd (300878) — Cash Flow Reinvestment Rate
Wecome Pharmaceutical Co Ltd (300878) has a Cash Flow Reinvestment Rate of 0.03x as of June 2025, reinvesting CN¥1.47 Million (capex CN¥389.97K plus investments CN¥-1.08 Million) from operating cash flow of CN¥50.89 Million. See 300878 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Wecome Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2013–2023)
Historical reinvestment intensity for Wecome Pharmaceutical Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Wecome Pharmaceutical Co Ltd.
Annual Cash Flow Reinvestment Rate for Wecome Pharmaceutical Co Ltd (2013–2023)
Year-by-year capital reinvestment analysis for Wecome Pharmaceutical Co Ltd. See Wecome Pharmaceutical Co Ltd (300878) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 6.52x | CN¥379.85 Million | CN¥58.29 Million | CN¥139.29 Million | ▲ +38.0% |
| 2022 | 4.72x | CN¥692.26 Million | CN¥146.57 Million | CN¥248.44 Million | ▲ +17.4% |
| 2020 | 4.02x | CN¥172.30 Million | CN¥42.81 Million | CN¥152.34 Million | ▲ +236.3% |
| 2019 | 1.20x | CN¥134.94 Million | CN¥112.76 Million | CN¥114.98 Million | ▼ -34.4% |
| 2018 | 1.83x | CN¥192.69 Million | CN¥105.57 Million | CN¥172.73 Million | ▼ -14.6% |
| 2017 | 2.14x | CN¥62.00 Million | CN¥29.00 Million | CN¥42.04 Million | ▲ +124.2% |
| 2016 | 0.95x | CN¥95.51 Million | CN¥100.15 Million | CN¥47.97 Million | ▼ -26.6% |
| 2015 | 1.30x | CN¥38.48 Million | CN¥29.63 Million | CN¥38.48 Million | ▲ +46.9% |
| 2014 | 0.88x | CN¥40.68 Million | CN¥46.01 Million | CN¥40.68 Million | ▲ +100.2% |
| 2013 | 0.44x | CN¥11.48 Million | CN¥25.98 Million | CN¥11.48 Million | — |